Committed to the development of new approach methodologies (NAM) in preclinical safety to support the drug discovery in compliance with the 3R principle (“reduce, refine, replace”) by using my background in neuropharmacology, my in vivo expertise, my experience in preclinical safety and my eternal curiosity for new technologies and strategies. During almost 6 years in preclinical Safety in pharmaceutical industry, I developed my skills in the conduct and strategy of in vivo studies and early toxicology projects in compliance with regulatory guidelines. I use to work in a translational team and I love it !I recently joined Eurofins Cerep (Eurofins Discovery group), a leader in cell and target-based assays in Safety Pharmacology and Toxicology to develop my skills in the in vitro and in silico worlds and to support our clients in their compound derisking strategies for human health.